Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...

This has hurt major AI players led by chipmaker Nvidia ( NVDA) , as the innovation threatens the demand for Nvidia's ...

Merck (MRK) announced that the board of directors has declared a quarterly dividend of 81c per share of the company’s common stock for the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.

Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $97.94 which represents a slight increase of $2.39 or 2.50% from the prior close of $95.55. The stock opened at $96.63 and touched a ...

Citi lowered the firm’s price target on Merck (MRK) to $125 from $130 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the firm ...